Avadel Pharmaceuticals plc (AVDL) NASDAQ
21.64
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Avadel Pharmaceuticals plc
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
188
First IPO Date
June 07, 1996
Key Executives
| Name | Title | Pay | Year Born |
| Gregory J. Divis Jr. | Chief Executive Officer & Director | 677,400 | 1967 |
| Thomas S. McHugh | Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer | 530,119 | 1965 |
| Jerad G. Seurer | General Counsel, Company Secretary & Compliance Officer | 634,700 | 1974 |
| Jason Vaughn | Senior Vice President of Technical Operations | 0 | N/A |
| Polly A. Murphy | Chief Business Officer | 0 | 1965 |
| Gregory J. Davis | Vice President of Corporate and Business Development | 0 | 1965 |
| Angie Woods | Vice President of People & Culture | 0 | N/A |
| Jennifer Gudeman | Senior Vice President of Medical & Clinical Affairs | 0 | N/A |
| Marla Scarola | Senior Vice President of Regulatory & Quality | 0 | N/A |
| Susan Rodriguez | Chief Operating Officer | 0 | 1965 |
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
